Weekly Research Analysts’ Ratings Updates for FibroGen (FGEN)

FibroGen (NASDAQ: FGEN) recently received a number of ratings updates from brokerages and research firms:

• 11/30/2024 – FibroGen is now covered by analysts at StockNews.com. They set a “hold” rating on the stock.
• 11/22/2024 – FibroGen is now covered by analysts at StockNews.com. They set a “hold” rating on the stock.
• 11/14/2024 – FibroGen is now covered by analysts at StockNews.com. They set a “hold” rating on the stock.
• 11/13/2024 – FibroGen had its “market perform” rating reaffirmed by analysts at William Blair.
• 11/6/2024 – FibroGen is now covered by analysts at StockNews.com. They set a “hold” rating on the stock.
• 10/29/2024 – FibroGen is now covered by analysts at StockNews.com. They set a “hold” rating on the stock.
• 10/21/2024 – FibroGen is now covered by analysts at StockNews.com. They set a “hold” rating on the stock.
• 10/13/2024 – FibroGen is now covered by analysts at StockNews.com. They set a “hold” rating on the stock.
• 10/5/2024 – FibroGen is now covered by analysts at StockNews.com. They set a “hold” rating on the stock.

FibroGen Stock Performance

NASDAQ FGEN remained flat at $0.42 during trading on Tuesday. The company’s stock had a trading volume of 989,920 shares, compared to its average volume of 1,321,370. The firm’s fifty day moving average price is $0.36 and its 200 day moving average price is $0.64. The stock has a market capitalization of $42.42 million, a P/E ratio of -0.34 and a beta of 0.82. FibroGen, Inc. has a 12-month low of $0.18 and a 12-month high of $2.93.

FibroGen (NASDAQ:FGEN) last released its earnings results on Tuesday, November 12th. The biopharmaceutical company reported ($0.17) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.38) by $0.21. The firm had revenue of $46.33 million during the quarter, compared to analyst estimates of $34.00 million. During the same quarter in the previous year, the firm earned ($0.52) EPS. On average, equities analysts predict that FibroGen, Inc. will post -0.86 earnings per share for the current year.

Institutional Trading of FibroGen

Hedge funds and other institutional investors have recently modified their holdings of the business. Point72 DIFC Ltd increased its stake in FibroGen by 734.2% in the 2nd quarter. Point72 DIFC Ltd now owns 52,254 shares of the biopharmaceutical company’s stock worth $47,000 after purchasing an additional 45,990 shares during the period. Doheny Asset Management CA purchased a new stake in FibroGen in the second quarter worth about $48,000. Accel Wealth Management increased its position in FibroGen by 117.5% during the 2nd quarter. Accel Wealth Management now owns 95,600 shares of the biopharmaceutical company’s stock valued at $85,000 after buying an additional 51,645 shares in the last quarter. Franklin Street Advisors Inc. NC bought a new position in FibroGen in the 2nd quarter worth about $89,000. Finally, Point72 Asia Singapore Pte. Ltd. purchased a new stake in FibroGen during the 2nd quarter valued at $130,000. Institutional investors own 72.71% of the company’s stock.

FibroGen, Inc, a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. Its lead product candidates are Pamrevlumab, a human monoclonal antibody targeting connective tissue growth factor that is in Phase III clinical development for the treatment of locally advanced pancreatic cancer; and Roxadustat, an oral small molecule inhibitor of hypoxia-inducible factor prolyl hydroxylase activity, which has completed Phase III clinical development for the treatment of anemia in chronic kidney disease in China, Europe, Japan, and other countries, as well as in Phase III clinical development for anemia related with myelodysplastic syndromes.